Monitor Q4 2026 revenue trajectory for RYTELO to see if demand growth sustains the 10% QoQ pace; watch for European launch uptake in Germany and France as a second growth leg; the IMpactMF discontinuation removes a key pipeline catalyst, increasing reliance on LR-MDS commercial execution.
Drug in focus
GERN drug pipeline →RYTELO
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (first commercial launch in Q3 2024)
- Next catalyst
- None dated
What to watchWatch the Q3 2026 earnings release on Nov 4, 2026 (consensus ~$60.4M revenue). The key question is whether RYTELO's revenue growth trajectory can accelerate from the ~11% QoQ pace, which would validate the revenue ramp thesis behind the $4+ analyst targets. The 7.39 days-to-cover short interest adds a squeeze potential if results surprise positively, but the shareholder lawsuit and high short volume ratio suggest significant skepticism about the commercial ramp.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $1.08entry
- T+1 · 12d ago −12.03%α −7.62% · $0.9501
- T+5 · 6d ago −5.56%α −4.64% · $1.02
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Geron reported Q3 2026 RYTELO net product revenue of $60.1M, beating the $60.4M consensus by a slight margin, and achieved net income of $1.4M ($0.00 per share) versus consensus EPS of -$0.01. The company reiterated its 2026 revenue guidance at the mid-to-high end of $220M-$240M and lowered its operating expense range to $220M-$230M. However, the discontinuation of the Phase 3 IMpactMF trial in myelofibrosis removes a key pipeline catalyst and increases reliance on the LR-MDS franchise.
Key Financial Metrics
Key Facts
- Q3 2026 RYTELO net product revenue $60.1M, up 5% QoQ and 27% YoY from $47.2M
- Net income of $1.4M ($0.00 per share) vs net loss of $18.4M ($0.03) in Q3 2025
- Total operating expenses fell to $54.4M from $61.1M YoY
- 2026 revenue guidance maintained at mid-to-high end of $220M-$240M
- 2026 total operating expense guidance lowered to $220M-$230M from $230M-$240M
- Phase 3 IMpactMF trial in myelofibrosis discontinued after DMC deemed unlikely to meet primary OS endpoint
- Cash and marketable securities $339.4M as of Sep 30, 2026, up from $326.9M at Jun 30, 2026
- Initiated gated European commercial launch; Germany availability expected by end of 2026
Financial Impact
Q3 revenue $60.1M slightly below $60.4M consensus; EPS $0.00 vs -$0.01 consensus beat; operating expenses lowered by $10M; pipeline setback eliminates potential future revenue stream
Risk Factors
- Discontinuation of Phase 3 IMpactMF trial eliminates a potential future revenue stream and increases dependency on LR-MDS
- Revenue guidance maintained at mid-to-high end of $220M-$240M implies Q4 revenue of $50.6M-$70.6M, a wide range
- European commercial launch is early stage with pricing, reimbursement and competitive risks
- Cash burn remains negative on an operating basis despite net income due to non-cash items
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395186 |
Track record
11 reports on GERN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $0.9742 Now $0.9400 −3.51% settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $0.9965 to $0.9419 Now $0.9400 −5.67% ▼ −5.48% −3.79% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Viewing Entry $1.08 to $1.02 Now $0.9400 −12.96% ▼ −5.56% −4.64% vs SPY
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 Now $0.9400 +0.66% ▼ −0.41% −5.14% vs SPY
- Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 Now $0.9400 −24.19% ▼ −6.85% −6.88% vs SPY
- Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 Now $0.9400 −27.69% ▼ −3.85% −2.83% vs SPY
- Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 Now $0.9400 −39.35% ▼ −2.26% −2.31% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $1.71 to $1.69 Now $0.9400 −45.03% ▼ −1.17% −4.69% vs SPY
- Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 Now $0.9400 −33.33% ▲ +23.40% +19.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers